<DOC>
	<DOCNO>NCT01052311</DOCNO>
	<brief_summary>Laropiprant ( LRP ; Merck &amp; Co. , Inc , Whitehouse Station , NJ , USA ) potent , once-daily , highly selective PGD2-receptor ( DP1 ) antagonist . A combination tablet contain 1 g extended-release niacin 20 mg laropiprant ( ERN/LRPT ) offer improved tolerability , support simplify 1-2 g dose paradigm improve adherence . Statins niacin improve endothelial function cardiac patient , however , data yet regard additive effect raise HDL-C ERN/LRPT statins endothelial function cardiac patient . Thus aim present study evaluate impact 3 month ' administration ERN/LRPT compare placebo add statin endothelial function , assess brachial artery vasoreactivity stable cardiac patient .</brief_summary>
	<brief_title>The Impact Tredaptive Flow-Mediated Dilation Cardiac Patients</brief_title>
	<detailed_description>Endothelial dysfunction reflect vascular phenotype prone atherogenesis may therefore serve marker inherent atherosclerotic risk . In line hypothesis , dysfunction either coronary peripheral vascular endothelium show constitute independent predictor cardiovascular event , provide valuable prognostic information additional derive conventional risk factor assessment . Interventions , risk factor modification treatment various drug , include statin niacin , may improve endothelial function lead potentially improve prognosis . Research past year identify numerous beneficial effect high-density lipoprotein ( HDL ) beyond property . These include , limited , improvement endothelial function , anti-inflammatory , anti-thrombotic , antioxidative effect stimulation endothelial regeneration . Consequently , therapeutic elevation HDL among primary goal treatment patient coronary artery disease ( CAD ) . Laropiprant ( LRP ; Merck &amp; Co. , Inc , Whitehouse Station , NJ , USA ) potent , once-daily , highly selective PGD2-receptor ( DP1 ) antagonist . A combination tablet contain 1 g extended-release niacin 20 mg laropiprant ( ERN/LRPT ) offer improved tolerability , support simplify 1-2 g dose paradigm improve adherence . Statins niacin improve endothelial function CAD patient , however , data yet regard additive effect raise HDL-C ERN/LRPT statins endothelial function CAD patient . Thus aim present study evaluate impact 3 month ' administration ERN/LRPT compare placebo add statin endothelial function , assess brachial artery vasoreactivity , platelet function stable CAD patient .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female ≥ 18 year ; sign informed consent 2 . Outpatient CAD patient statin therapy . 3 . HDLC &lt; 40 mg/dL male &lt; 50 mg/dL female . 4 . Left ventricular ( LV ) systolic dysfunction ≥ 40 % measure within past 6 month . 5 . No change cardiac medication 2 week prior enrollment . Exclusion criterion : 1 . Presence transplant tissue organ LVAD 2 . AICD CRT CRTD patient . 3 . Acute MI , CABG , PCI within past 3 month . 4 . Congestive heart failure ( CHF ) ≥ NYHA 2 . 5 . Ejection fraction &lt; 40 % measure within past 6 month . 6 . Malignancy . 7 . Active myocarditis , cardiomyopathy . 8 . HIV infection immunodeficiency state . 9 . Chronic viral infection . 10 . Acute systemic infection require antibiotic . 11 . Chronic diarrhea malabsorption . 12 . Statin therapy initiation ≤ 3 month . 13 . Diabetes mellitus type 1 . 14 . Diabetes mellitus type 2 HbA1C &gt; 7 % 15 . Lowdensity lipoprotein cholesterol ( LDLC ) &gt; 100 mg/dL . 16 . Not statin therapy . 17 . Liver function test ( LFT ) ≥ x 3 upper limit normal ( ULN ) creatinine kinase ( CPK ) ≥ x 10 ULN . 18 . Hypo/hyper thyroidism . 19 . Liver dysfunction . 20 . Renal failure serum creatinine ≥ 2 mg/dL . 21 . Alcohol drug abuse . 22 . Refuse sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Coronary artery disease</keyword>
	<keyword>Endothelial function</keyword>
	<keyword>Platelet function</keyword>
	<keyword>Statins</keyword>
	<keyword>Niacin</keyword>
</DOC>